Market research
003120.KO Ilsung Pharmaceuticals Co., Ltd
KO KRW Healthcare
Latest close
Loading market data…
Test a moving-average rule with historical data.
Market facts
- Market cap
- 156B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 5.5%
- Beta
- -0.19
Profile
Company facts
- Exchange
- KO
- Currency
- KRW
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- ISIN
- KR7003120003
- Market cap
- 156B
- P/E ratio
- Not available
- Analyst target
- Not available
- Dividend yield
- 5.5%
- Beta
- -0.19
About
About Ilsung Pharmaceuticals Co., Ltd
Ilsung Is Co., Ltd. operates as a pharmaceutical company in South Korea. Its products include antibiotics, analgesics, muscle relaxants, antipyretic-analgesics, antihistamine, neuropsychiatric, neuromuscular blocker/ central muscle relaxants, anti-coagulants, probiotics, vaccine, medical equipment, circulatory system drugs, contrast agents, muscle relaxants, diabetes treatments, osteopathic, digestive system medicines, anti-virals, anti-emetics, respiratory treatments, adrenal cortical steroids, anesthetics, antipyretics, and cardiovascular system products. The company was formerly known as Ilsung Pharmaceuticals Co., Ltd. and changed its name to Ilsung Is Co., Ltd. in April 2024. Ilsung Is Co., Ltd. was founded in 1954 and is headquartered in Seoul, South Korea.
Visit company websiteCommunity
Investor discussion
1 comment
Sign in to join the 003120.KO discussion.
5 years, 5 months ago
Ilsung Pharmaceuticals Co., Ltd is currently in a long term uptrend where the price is trading 2.8% above its 200 day moving average.
From a valuation standpoint, the stock is 63.8% cheaper than other stocks from the Healthcare sector with a price to sales ratio of 3.1.
Ilsung Pharmaceuticals Co., Ltd's total revenue sank by 21.1% to $10B since the same quarter in the previous year.
Its net income has dropped by 38.4% to $2B since the same quarter in the previous year.
Finally, its free cash flow fell by 847.7% to $-6B since the same quarter in the previous year.
Based on the above factors, Ilsung Pharmaceuticals Co., Ltd gets an overall score of 2/5.